MacroGenics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics primarily for cancer treatment. Its approved product, MARGENZA (margetuximab-cmkb), targets HER2-positive metastatic breast cancer in adult patients who have received prior anti-HER2 therapies. The company's robust pipeline features innovative candidates leveraging proprietary DART (Dual-Affinity Re-Targeting) molecules and antibody-drug conjugates (ADCs). Key investigational assets include lorigerlimab, a bispecific DART targeting PD-1 and CTLA-4 checkpoints; MGC026, an ADC against B7-H3 with a novel topoisomerase I inhibitor payload; and MGC028, targeting ADAM9 with a similar advanced payload technology. Additional pipeline products address various tumor-associated antigens and immune checkpoints. MacroGenics Inc. operates in the competitive oncology sector, advancing precision therapies to modulate immune responses and deliver targeted cytotoxicity. Founded in 2000 and headquartered in Rockville, Maryland, it plays a vital role in the biotechnology landscape by pushing boundaries in immuno-oncology and ADC innovations.